Guillaume Manson - Concepedia

Author

Guillaume Manson

Centre Hospitalier Universitaire de Rennes ORCID

Also Known As

G. MANSON, G. Manson, Guillaume Manson, Sue Mahler

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

Centre Hospitalier Universitaire de Rennes Inserm Assistance Publique – Hôpitaux de Paris Institut Gustave Roussy Centre Hospitalier Universitaire de Lille

About

Guillaume Manson is an author at Centre Hospitalier Universitaire de Rennes specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	253
2	Immunology	6	6	253
3	Blood Transplantation	1	1	77
4	Cellular Therapies	1	1	43
5	Marrow Transplantation	1	1	43

Guillaume Manson

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma Emmanuel Bachy, Steven Le Gouill, Roberta Di Blasi, Nature Medicine	2022	343
Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma Charles Herbaux, Jordan Gauthier, Pauline Brice, Blood	2017	215
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study Guillaume Manson, Alexandre Maria, F. Poizeau, Journal for ImmunoTherapy of Cancer	2019	102
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma Reid W. Merryman, Luca Castagna, Laura Giordano, Leukemia Lymphoid NeoplasiaTransplantationMedicineImmunologyBlood Transplantation	2021	77
Anti–programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study Marion Panhaleux, Olivier Espitia, Benjamin Terrier, European Journal of Cancer Cancer ImmunosurveillanceOncologyAutoimmune DiseaseSystemic TreatmentImmune Regulation	2021	46
Early <sup>18</sup>F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab Aiping Chen, Fatima‐Zohra Mokrane, Lawrence H. Schwartz, Journal of Nuclear Medicine	2019	45
Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists Gaëlle Drillet, Faustine Lhomme, Sophie de Guibert, Blood Advances ThrombopoiesisThrombosisThrombopoietin Receptor AgonistsBlood PlateletT-regulatory Cell	2022	44
Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation Guillaume Manson, Jean-Baptiste Méar, Charles Herbaux, European Journal of Cancer Lymphoid NeoplasiaCell TherapyHodgkin LymphomaTransplantationLong-term Efficacy	2019	43
Nivolumab Is Effective and Reasonably Safe in Relapsed or Refractory Hodgkin's Lymphoma after Allogeneic Hematopoietic Cell Transplantation: A Study from the Lysa and SFGM-TC Charles Herbaux, Jordan Gauthier, Pauline Brice, Blood	2015	36
Performance of CT Compared with <sup>18</sup>F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma Fatima‐Zohra Mokrane, Aiping Chen, Lawrence H. Schwartz, Radiology	2020	35

Page 1